

« Les Journées du Pôle »
INNOVATION et RECHERCHE CLINIQUE
24 Novembre 2016

**La cancérogenèse
&
le mode d'action des thérapies ciblées**

Pr. Marie-Dominique GALIBERT


UMR 6290 CNRS / Université de Rennes 1
Institut de Génétique et Développement de Rennes



Service de Génétique Moléculaire et de Génomique Médicale
CHU de Rennes - Hôpital Pontchaillou




Cancers du sein (1)



Histoire Naturelle:

Anomalies Moléculaires


Origine Exogène



Origine Endogène

Erreurs de réPLICATION
Déamination spontanée
...

Histoire Naturelle: Les différentes étapes de Développement d'un Cancer



MUTATIONS:


DRIVER

PASSENGER


➤ ONCOGENE

➤ GENE SUPRESSEUR

ONCOGENES : « Onkos = masse »



ONCOGENE



KRAS, NRAS


BRAF

EGFR

cMYC

...

GENE SUPRESSEUR



p53



Rb

PTEN

CDKN2A

BRCA1/2 ...


Cutaneous melanoma



B-RAF: “cible biologique”




- Mutation Récurrente - Précoce - Déetectable
- Voie de la prolifération / en amont

B-RAF: cible thérapeutique



Adapted from Luke & Ott, 2014, *Drug Healthcare and Patient Safety*


8




AcSé **vemurafenib**




Colorectal Cancer: Multistep Carcinogenesis




EGFR signalling pathway → Tumor Growth → anti-EGFR mAbs : Cetuximab



ONCOGENE



GENE SUPRESSEUR



KRAS, NRAS

BRAF

EGFR

...

p53


Rb

PTEN


CDKN2A

BRCA1/2 ...

Cancers du sein et de l'ovaire perte de fonction de BRCA



Cancers du sein et de l'ovaire perte de fonction de BRCA



→ Létalité synthétique : inhibiteurs de PARP poly-ADP-ribose-polymerase-1

TAKE HOME MESSAGE

➤ Transformation tumorale : multistep

➤ Activation Oncogène

- TKi
- Anticorps blocant

➤ Perte de Gène Supresseur

- Action détournée